Atea Pharmaceuticals, Inc. (AVIR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Atea Pharmaceuticals reported revenue of $0. Net income was -$158.3M, or -$1.94 per diluted share. Operating activities generated -$132.0M of cash. At fiscal year end, Atea Pharmaceuticals held $315.2M in total assets against $39.8M in total liabilities, including $95.7M of cash and equivalents.
Open the full interactive Atea Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Atea Pharmaceuticals Key Stats
| Share Price | $4.98 |
|---|---|
| Market Cap | $398.7M |
| 52-Week Range | $2.96 – $6.15 |
| Shares Outstanding | 80.1 million (basic, 2026 Q2) |
Atea Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $48.6M | $351.4M | $0 | $0 | $0 | $0 |
| Operating Income | -$11.0M | $138.4M | -$130.7M | -$164.2M | -$192.9M | -$180.9M |
| Pre-Tax Income | -$10.9M | $138.6M | -$119.5M | -$134.9M | -$167.5M | -$164.5M |
| Income Tax | — | $17.4M | -$3.6M | $1.0M | $925,000 | -$6.2M |
| Net Income | -$10.9M | $121.2M | -$115.9M | -$136.0M | -$168.4M | -$158.3M |
| Diluted EPS | -$0.51 | $1.37 | -$1.39 | -$1.63 | -$2.00 | -$1.94 |
Atea Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$42.0M | -$44.9M | -$45.4M | -$32.9M |
| Diluted EPS | -$0.53 | -$0.55 | -$0.57 | -$0.41 |
Atea Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $850.1M | $764.4M | $188.5M | $143.8M | $64.7M | $95.7M |
| Current Assets | $863.5M | $772.4M | $660.9M | $590.5M | $462.4M | $311.0M |
| Total Assets | $863.6M | $772.9M | $666.7M | $595.0M | $464.7M | $315.2M |
| Current Liabilities | $315.8M | $56.9M | $18.5M | $32.4M | $18.6M | $39.8M |
| Total Liabilities | $315.8M | $62.8M | $26.1M | $39.8M | $25.8M | $39.8M |
| Shareholders' Equity | $547.8M | $710.1M | $640.6M | $555.2M | $438.9M | $275.4M |
Atea Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $296.7M | -$87.0M | -$121.0M | -$85.4M | -$135.5M | -$132.0M |
| Cash From Investing | -$26,000 | -$4,000 | -$455.4M | $40.3M | $56.1M | $188.8M |
| Cash From Financing | $531.7M | $1.5M | $370,000 | $257,000 | $267,000 | -$25.7M |
| Free Cash Flow | $296.7M | -$87.0M | -$122.9M | -$87.3M | — | — |
Figures from Atea Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Atea Pharmaceuticals financials page for every line item.
Atea Pharmaceuticals Company Profile
| Ticker | AVIR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001593899 |
Frequently Asked Questions
What was Atea Pharmaceuticals' revenue in fiscal 2025?
Atea Pharmaceuticals (AVIR) reported revenue of $0 for fiscal 2025.
What is Atea Pharmaceuticals' annual revenue history?
Atea Pharmaceuticals' annual revenue by fiscal year: 2020: $48.6M; 2021: $351.4M; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Atea Pharmaceuticals' net income in fiscal 2025?
Atea Pharmaceuticals reported net income of -$158.3M for fiscal 2025.
What was Atea Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Atea Pharmaceuticals' diluted EPS was -$1.94 for fiscal 2025 (adjusted for any later stock splits).
What was Atea Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Atea Pharmaceuticals reported revenue of $0.
How many shares of Atea Pharmaceuticals are outstanding?
Atea Pharmaceuticals reported a weighted average of 80.1 million basic shares outstanding in 2026 Q2.
What is Atea Pharmaceuticals' market cap?
Based on its latest closing price, Atea Pharmaceuticals (AVIR) has a market capitalization of about $398.7M.
When does Atea Pharmaceuticals' fiscal year end?
Atea Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Atea Pharmaceuticals headquartered?
Atea Pharmaceuticals lists its business address in Boston, Massachusetts in its SEC filings.